Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Kivu Bioscience Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
USWM, LLC (dba US WorldMeds)
Conjupro Biotherapeutics, Inc.
Pfizer
Erasca, Inc.
Eli Lilly and Company
GlaxoSmithKline
Mayo Clinic
Stanford University
ViroMissile, Inc.
Pfizer
Pfizer
Tizona Therapeutics, Inc
ALX Oncology Inc.
Clasp Therapeutics, Inc.
MacroGenics
Adaptimmune
Solve Therapeutics
Pierre Fabre Medicament
OncoNano Medicine, Inc.
Memorial Sloan Kettering Cancer Center
University of Chicago
AccSalus Biosciences, Inc.
Therorna
Incyte Corporation
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Nurix Therapeutics, Inc.
Memgen, Inc.
Incyte Corporation
University of California, San Diego
AbbVie
Scholar Rock, Inc.
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Carisma Therapeutics Inc
Symphogen A/S
Acepodia Biotech, Inc.
Taiho Pharmaceutical Co., Ltd.
Pfizer
Zhejiang University
Pfizer
University of California, San Francisco
Wellmarker Bio
Yale University
Adaptimmune